Is it worth getting into Google

BioNTech shares: is it still worth investing in the vaccine manufacturer?

The value of the success of BioNTech even increases when you compare the Rhineland-Palatinate pharmaceutical company with other companies that took part in the race for a vaccine against the coronavirus. Some vaccine candidates failed early on and others, such as those from Johnson & Johnson or AstraZeneca, did not reach the level of effectiveness of BioNTech's mRNA vaccine.

The latest reports also speak for the continued success of the collaboration between BioNTech and Pfizer. For example, Albert Bourla, Chairman of Pfizer, recently announced that BioNTech / Pfizer would be able "to develop and apply for approval for a customized mRNA vaccine or booster if necessary."

The question of the effectiveness of the vaccine against new virus mutations is fundamental for the course of the pandemic, for the company and for investors. The BioNTech vaccine can score two big pluses here. On the one hand, it has also proven to be effective with the virus mutations discovered so far, and on the other hand, the mRNA vaccines can be optimized in a relatively short time. In this way, the company can provide answers to changed framework conditions more quickly to new variants or mutants of the coronavirus than, for example, AstraZeneca, whose vaccine is based on weakened cold viruses from chimpanzees.

Since the new virus mutations are considered to be more contagious, BioNTech provides some arguments for investors who expect the stock to have further potential. Because when it first ordered vaccines, the EU distributed the quantities to various pharmaceutical companies whose vaccines were considered promising at the time. Today we know that the Mainz-based pharmaceutical company was able to deliver the fastest and is most effective. Thanks to this now secured information, the EU was recently able to increase the order quantity and has secured a further 300 million vaccine doses. Two thirds of these are to be delivered this year. If you take into account the population of the EU, almost every inhabitant of an EU member state could be vaccinated with the Biontech vaccine.

BioNTech - the signs point to expansion

BioNTech boss Ugur Sahin did not have his own production capacities until recently. BioNTech was a respected, but also relatively small, research-based pharmaceutical company. Because of this, the company from the Rhine was initially unable to meet the enormous demand for the vaccine. This situation is counteracted by means of collaborations with production facilities and the expansion of the Mainz location. BioNTech will move into its new laboratories and offices there by 2022 at the latest.

BioNTech share - a future outlook

In contrast to values ​​where valuation and real business expectations seem to diverge, Behind the stock market success of BioNTech / Pfizer is a real, tangible success story. The small company from Rhineland-Palatinate has the most coveted "product" in the current exceptional situation. And the people of Mainz around Ugur Sahin are investing massively in the near future.

Current BioNTech is planning a study on booster vaccination through a third vaccine dose. The aim of this is to investigate how much additional security a third dose offers and how this affects immunization against the virus strains currently in circulation. The subjects are participants in the phase 1 study who have already received 2 doses as part of the study.

In this regard, Sahin also speaks of a "proactive clinical development strategy" that aims to acquire the basics in order to be able to respond to short-term challenges. In the state capital of Rhineland-Palatinate one leaves no doubt that one wants to be and will be prepared for every pandemic change.

Conclusion

BioNTech joins other representatives of the biotech industry who are on the rise and are also interesting as investments. The Mainz vaccine manufacturer's share has multiplied, consolidated at the turn of the year and increased again at the beginning of 2021. As early as autumn 2019, some analysts recommended the BioNTech share as a buy. At that time at a rate of 11.70 euros. At a current price of 90.50 euros (as of March 2, 2021), well-known analysts see the price target at 120 US dollars.

If you want to benefit from BioNTech shares, or if you want to learn more about other interesting biotech companies, you will find everything you need to know in this guide on biotech shares from aktien.net. In addition to share valuations, you will also find information on the best biotech ETFs as well as broker experience and practical tools such as a comparison calculator.